StockData
BioAtla, Inc. logo

BioAtla, Inc. (BCAB) company profile

BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$1.31−0.05 (-3.68%)

Close on Oct 19, 2026Market cap $2.18MP/E –Yield –

About BioAtla

Biological Products, (No Diagnostic Substances), SIC 2836

BioAtla is a clinical-stage biopharmaceutical company that discovers and engineers conditionally active antibody therapeutics for the treatment of solid tumor cancers. Utilizing its proprietary Conditionally Active Biologics platform, the company designs therapeutic candidates—including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies—that selectively target cancer cells in acidic tumor microenvironments while sparing healthy tissues. Key pipeline assets include BA3182, an EpCAM- and CD3-targeting bispecific candidate evaluated in advanced adenocarcinoma, and ozuriftamab vedotin, a ROR2-directed antibody-drug conjugate studied in oropharyngeal squamous cell carcinoma. The firm aims to serve cancer patients by developing oncological therapies that reduce systemic toxicity and expand treatable target antigens.

The company operates without internal manufacturing facilities, outsourcing clinical trial drug supply, filling, packaging, storage, and distribution to third-party contract manufacturers. As of February 1, 2026, its intellectual property portfolio comprises 597 issued patents, 13 allowed applications, and 258 pending applications across multiple jurisdictions. The provided text does not identify headquarters or specific operating countries.

Summary of the business section of BioAtla's latest annual report, written by StockData.

Company profile

Company

Legal name
BioAtla, Inc.
Headquarters
San Diego, CA
Address
11085 Torreyana Road 92121
Phone
(858) 558-0708
Employees
41, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
BCAB
Exchange
OTC
IPO date
Dec 17, 2020
Shares outstanding
2M, Aug 10, 2026
Public float
$18.70M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-50 reverse, Apr 6, 2026
SEC CIK
1826892
CUSIP
09077B203
ISIN
US09077B2034
FIGI
BBG00Y6GBT61
Share class FIGI
BBG00Y6GBV39
EIN
85-1922320

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jay M. Short PhdChief Executive Officer, Director84,300
Eric SieversChief Medical Officer11,346
Christian VasquezChief Financial Officer10,476
Richard A. WaldronFormer Chief Financial Officer343,421
Eddie WilliamsDirector60,200
Mary Ann GrayDirector77,397
Scott Andrew SmithDirector321,550
Susan MoranDirector52,307
Lawrence SteinmanDirector78,459
Sylvia McBrinnDirector59,125

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$879.25K$866.13K$550.29K$7–
FY2024$1.95M$1.24M$921.39K$7–
FY2023$3.30M$154.54K$1.27M$30–
FY2022$2.54M-$3.09M$1.15M$42–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsTotalvs. prior year
Jay M. Short, Ph.D.
Chief Executive Officer, Co-founder, and Chairman of the Board of Directors
$734.82K$144.43K$879.25K-55%
Richard A. Waldron
Chief Financial Officer
$485.45K$30.73K$516.18K-41%
Eric Sievers, M.D.
Chief Medical Officer
$530.63K$53.78K$584.41K-39%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Dec 17, 2020
Offer price
$18.00
Securities offered
10,500,000
Gross proceeds
$189.00M
Exchange
Nasdaq
First trading day
Dec 16, 2020
First-day close
$31.02+72.3%
Lock-up ends (est.)
Jun 14, 2021

“The initial public offering price of our common stock is $18.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 41 employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?